{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:39:27Z","timestamp":1793936367619,"version":"4.8.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1038\/s41584-020-0395-3","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T14:02:21Z","timestamp":1583848941000},"page":"282-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1072-6994","authenticated-orcid":false,"given":"Jose U.","family":"Scher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renuka R.","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Ubeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0888-2875","authenticated-orcid":false,"given":"Peter J.","family":"Turnbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven B.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"key":"395_CR1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205\u20132219 (2011).","journal-title":"N. Engl. J. Med."},{"key":"395_CR2","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman, D. D., Antoni, C., Mease, P., Clegg, D. O. & Nash, P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64, ii14\u2013ii17 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"395_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.rdc.2015.07.006","volume":"41","author":"JL Barnas","year":"2015","unstructured":"Barnas, J. L. & Ritchlin, C. T. Etiology and pathogenesis of psoriatic arthritis. Rheum. Dis. Clin. North Am. 41, 643\u2013663 (2015).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"395_CR4","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog, J. D., Chhabra, A. & Colbert, R. A. Ankylosing spondylitis and axial spondyloarthritis. N. Engl. J. Med. 374, 2563\u20132574 (2016).","journal-title":"N. Engl. J. Med."},{"key":"395_CR5","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","volume":"10","author":"J Keffer","year":"1991","unstructured":"Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025\u20134031 (1991).","journal-title":"EMBO J."},{"key":"395_CR6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes, I. B. et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386, 1137\u20131146 (2015).","journal-title":"Lancet"},{"key":"395_CR7","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease, P. J. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52, 3279\u20133289 (2005).","journal-title":"Arthritis Rheum."},{"key":"395_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","volume":"372","author":"P Emery","year":"2008","unstructured":"Emery, P. et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372, 375\u2013382 (2008).","journal-title":"Lancet"},{"key":"395_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/srep32768","volume":"6","author":"W Liu","year":"2016","unstructured":"Liu, W. et al. Efficacy and safety of TNF-alpha inhibitors for active ankylosing spondylitis patients: multiple treatment comparisons in a network meta-analysis. Sci. Rep. 6, 32768 (2016).","journal-title":"Sci. Rep."},{"key":"395_CR10","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten, D. et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373, 2534\u20132548 (2015).","journal-title":"N. Engl. J. Med."},{"key":"395_CR11","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee, E. B. et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370, 2377\u20132386 (2014).","journal-title":"N. Engl. J. Med."},{"key":"395_CR12","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman, D. et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N. Engl. J. Med. 377, 1525\u20131536 (2017).","journal-title":"N. Engl. J. Med."},{"key":"395_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh, A. et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 73, 1020\u20131026 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"395_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nrrheum.2016.68","volume":"12","author":"S Abdollahi-Roodsaz","year":"2016","unstructured":"Abdollahi-Roodsaz, S., Abramson, S. B. & Scher, J. U. The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions. Nat. Rev. Rheumatol. 12, 446\u2013455 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"395_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3111\/13696998.2014.914031","volume":"17","author":"JR Curtis","year":"2014","unstructured":"Curtis, J. R. et al. Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. J. Med. Econ. 17, 555\u2013566 (2014).","journal-title":"J. Med. Econ."},{"key":"395_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrrheum.2011.121","volume":"7","author":"JU Scher","year":"2011","unstructured":"Scher, J. U. & Abramson, S. B. The microbiome and rheumatoid arthritis. Nat. Rev. Rheumatol. 7, 569\u2013578 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"395_CR17","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01202","volume":"2","author":"JU Scher","year":"2013","unstructured":"Scher, J. U. et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2, e01202 (2013).","journal-title":"eLife"},{"key":"395_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/art.38892","volume":"67","author":"JU Scher","year":"2015","unstructured":"Scher, J. U. et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 67, 128\u2013139 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"395_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag2770","volume":"356","author":"N Koppel","year":"2017","unstructured":"Koppel, N., Maini Rekdal V. & Balskus E. P. Chemical transformation of xenobiotics by the human gut microbiota. Science 356, eaag2770 (2017).","journal-title":"Science"},{"key":"395_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1757-4749-4-16","volume":"4","author":"R Saad","year":"2012","unstructured":"Saad, R., Rizkallah, M. R. & Aziz, R. K. Gut pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog. 4, 16 (2012).","journal-title":"Gut Pathog."},{"key":"395_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s13238-018-0547-2","volume":"9","author":"M Doestzada","year":"2018","unstructured":"Doestzada, M. et al. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell 9, 432\u2013445 (2018).","journal-title":"Protein Cell"},{"key":"395_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2174\/187569210792246326","volume":"8","author":"MSR Rizkallah","year":"2010","unstructured":"Rizkallah M. S. R. & Aziz, R. K. The Human Microbiome Project, personalized medicine and the birth of pharmacomicrobiomics. Curr. Pharmacogenomics Person. Med. 8, 182\u2013193 (2010).","journal-title":"Curr. Pharmacogenomics Person. Med."},{"key":"395_CR23","first-page":"23","volume":"120","author":"Tr\u00e9fou\u00ebl JeT","year":"1935","unstructured":"JeT, Tr\u00e9fou\u00ebl, Nitti, F. & Bovet, D. Activit\u00e9 du p-aminoph\u00e9nylsulfamide surl\u2019infection streptococcique exp\u00e9rimentar de la souris et du lapin. CR Soc. Biol. 120, 23 (1935).","journal-title":"CR Soc. Biol."},{"key":"395_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1126\/science.6857239","volume":"220","author":"V Butler","year":"1983","unstructured":"Butler, V., Neu, H. & Lindenbaum, J. Digoxin-inactivating bacteria: identification in human gut flora. Science 220, 325\u2013327 (1983).","journal-title":"Science"},{"key":"395_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1126\/science.aar2946","volume":"359","author":"C Jobin","year":"2018","unstructured":"Jobin, C. Precision medicine using microbiota. Science 359, 32\u201334 (2018).","journal-title":"Science"},{"key":"395_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.tips.2016.10.001","volume":"38","author":"TM Kuntz","year":"2017","unstructured":"Kuntz, T. M. & Gilbert, J. A. Introducing the microbiome into precision medicine. Trends Pharmacol. Sci. 38, 81\u201391 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"395_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature11053","volume":"486","author":"T Yatsunenko","year":"2012","unstructured":"Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222\u2013227 (2012).","journal-title":"Nature"},{"key":"395_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1126\/science.aad9378","volume":"352","author":"T Gensollen","year":"2016","unstructured":"Gensollen, T., Iyer, S. S., Kasper, D. L. & Blumberg, R. S. How colonization by microbiota in early life shapes the immune system. Science 352, 539\u2013544 (2016).","journal-title":"Science"},{"key":"395_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature07540","volume":"457","author":"PJ Turnbaugh","year":"2009","unstructured":"Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480\u2013484 (2009).","journal-title":"Nature"},{"key":"395_CR30","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1126\/science.1223813","volume":"336","author":"JK Nicholson","year":"2012","unstructured":"Nicholson, J. K. et al. Host-gut microbiota metabolic interactions. Science 336, 1262\u20131267 (2012).","journal-title":"Science"},{"key":"395_CR31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1146\/annurev-immunol-020711-074937","volume":"30","author":"K Honda","year":"2012","unstructured":"Honda, K. & Littman, D. R. The microbiome in infectious disease and inflammation. Annu. Rev. Immunol. 30, 759\u2013795 (2012).","journal-title":"Annu. Rev. Immunol."},{"key":"395_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.07.009","volume":"363","author":"T Sousa","year":"2008","unstructured":"Sousa, T. et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. 363, 1\u201325 (2008).","journal-title":"Int. J. Pharm."},{"key":"395_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/cpt.1505","volume":"106","author":"C Birer","year":"2019","unstructured":"Birer, C. & Wright, E. S. Capturing the complex interplay between drugs and the intestinal microbiome. Clin. Pharmacol. Ther. 106, 501\u2013504 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"395_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau6323","volume":"364","author":"V Maini Rekdal","year":"2019","unstructured":"Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J. & Balskus, E. P. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 364, eaau6323 (2019).","journal-title":"Science"},{"key":"395_CR35","first-page":"555","volume":"181","author":"MA Peppercorn","year":"1972","unstructured":"Peppercorn, M. A. & Goldman, P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J. Pharmacol. Exp. Ther. 181, 555\u2013562 (1972).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"395_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0622-6","volume":"14","author":"RR Nayak","year":"2016","unstructured":"Nayak, R. R. & Turnbaugh, P. J. Mirror, mirror on the wall: which microbiomes will help heal them all? BMC Med. 14, 72 (2016).","journal-title":"BMC Med."},{"key":"395_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10203-6","volume":"7","author":"AK Sharma","year":"2017","unstructured":"Sharma, A. K., Jaiswal, S. K., Chaudhary, N. & Sharma, V. K. A novel approach for the prediction of species-specific biotransformation of xenobiotic\/drug molecules by the human gut microbiota. Sci. Rep. 7, 9751 (2017).","journal-title":"Sci. Rep."},{"key":"395_CR38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrmicro.2016.17","volume":"14","author":"P Spanogiannopoulos","year":"2016","unstructured":"Spanogiannopoulos, P., Bess, E. N., Carmody, R. N. & Turnbaugh, P. J. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat. Rev. Microbiol. 14, 273\u2013287 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"395_CR39","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.1124234","volume":"312","author":"SR Gill","year":"2006","unstructured":"Gill, S. R. et al. Metagenomic analysis of the human distal gut microbiome. Science 312, 1355 (2006).","journal-title":"Science"},{"key":"395_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature11234","volume":"486","author":"Human Microbiome Project.","year":"2012","unstructured":"Human Microbiome Project. Structure, function and diversity of the healthy human microbiome. Nature 486, 207\u2013214 (2012).","journal-title":"Nature"},{"key":"395_CR41","doi-asserted-by":"publisher","first-page":"137rv136","DOI":"10.1126\/scitranslmed.3004244","volume":"4","author":"E Holmes","year":"2012","unstructured":"Holmes, E. et al. Therapeutic modulation of microbiota-host metabolic interactions. Sci. Transl Med. 4, 137rv136 (2012).","journal-title":"Sci. Transl Med."},{"key":"395_CR42","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","volume":"570","author":"M Zimmermann","year":"2019","unstructured":"Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R. & Goodman, A. L. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 570, 462\u2013467 (2019).","journal-title":"Nature"},{"key":"395_CR43","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1046\/j.1365-2672.2001.01316.x","volume":"90","author":"D Couteau","year":"2001","unstructured":"Couteau, D., McCartney, A. L., Gibson, G. R., Williamson, G. & Faulds, C. B. Isolation and characterization of human colonic bacteria able to hydrolyse chlorogenic acid. J. Appl. Microbiol. 90, 873\u2013881 (2001).","journal-title":"J. Appl. Microbiol."},{"key":"395_CR44","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJM198110013051403","volume":"305","author":"J Lindenbaum","year":"1981","unstructured":"Lindenbaum, J., Rund, D. G., Butler, V. P. Jr., Tse-Eng, D. & Saha, J. R. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N. Engl. J. Med. 305, 789\u2013794 (1981).","journal-title":"N. Engl. J. Med."},{"key":"395_CR45","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1126\/science.1235872","volume":"341","author":"HJ Haiser","year":"2013","unstructured":"Haiser, H. J. et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295\u2013298 (2013).","journal-title":"Science"},{"key":"395_CR46","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4161\/gmic.27915","volume":"5","author":"HJ Haiser","year":"2014","unstructured":"Haiser, H. J., Seim, K. L., Balskus, E. P. & Turnbaugh, P. J. Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes 5, 233\u2013238 (2014).","journal-title":"Gut Microbes"},{"key":"395_CR47","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.33953","volume":"7","author":"N Koppel","year":"2018","unstructured":"Koppel, N., Bisanz, J. E., Pandelia, M. E., Turnbaugh, P. J. & Balskus, E. P. Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins. eLife 7, e33953 (2018).","journal-title":"eLife"},{"key":"395_CR48","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1211\/jpp\/61.10.0005","volume":"61","author":"M Niehues","year":"2009","unstructured":"Niehues, M. & Hensel, A. In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability? J. Pharm. Pharmacol. 61, 1303\u20131307 (2009).","journal-title":"J. Pharm. Pharmacol."},{"key":"395_CR49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1124\/jpet.111.191122","volume":"341","author":"A LoGuidice","year":"2012","unstructured":"LoGuidice, A., Wallace, B. D., Bendel, L., Redinbo, M. R. & Boelsterli, U. A. Pharmacologic targeting of bacterial beta-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J. Pharmacol. Exp. Ther. 341, 447\u2013454 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"395_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006958","volume":"4","author":"B Bjorkholm","year":"2009","unstructured":"Bjorkholm, B. et al. Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS One 4, e6958 (2009).","journal-title":"PLoS One"},{"key":"395_CR51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","volume":"472","author":"Z Wang","year":"2011","unstructured":"Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57\u201363 (2011).","journal-title":"Nature"},{"key":"395_CR52","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1109400","volume":"368","author":"WH Tang","year":"2013","unstructured":"Tang, W. H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. 368, 1575\u20131584 (2013).","journal-title":"N. Engl. J."},{"key":"395_CR53","doi-asserted-by":"publisher","first-page":"21307","DOI":"10.1073\/pnas.1215689109","volume":"109","author":"S Craciun","year":"2012","unstructured":"Craciun, S. & Balskus, E. P. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc. Natl Acad. Sci. USA 109, 21307\u201321312 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"395_CR54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00008571-199702000-00005","volume":"7","author":"H Nakayama","year":"1997","unstructured":"Nakayama, H. et al. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics 7, 35\u201343 (1997).","journal-title":"Pharmacogenetics"},{"key":"395_CR55","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/17425255.2018.1530216","volume":"14","author":"RK Aziz","year":"1918","unstructured":"Aziz, R. K., Hegazy, S. M., Yasser, R., Rizkallah, M. R. & ElRakaiby, M. T. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions. Expert. Opin. Drug. Metab. Toxicol. 14, 1043\u201310553 (1918).","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"395_CR56","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1126\/science.1191175","volume":"330","author":"BD Wallace","year":"2010","unstructured":"Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831\u20138353 (2010).","journal-title":"Science"},{"key":"395_CR57","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1126\/science.6836275","volume":"220","author":"JR Saha","year":"1983","unstructured":"Saha, J. R., Butler, V. P. Jr., Neu, H. C. & Lindenbaum, J. Digoxin-inactivating bacteria: identification in human gut flora. Science 220, 325\u20133273 (1983).","journal-title":"Science"},{"key":"395_CR58","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1124\/dmd.118.083402","volume":"46","author":"JE Bisanz","year":"2018","unstructured":"Bisanz, J. E., Spanogiannopoulos, P., Pieper, L. M., Bustion, A. E. & Turnbaugh, P. J. How to determine the role of the microbiome in drug disposition. Drug. Metab. Dispos. 46, 1588\u20131595 (2018).","journal-title":"Drug. Metab. Dispos."},{"key":"395_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1242\/dmm.017400","volume":"8","author":"TL Nguyen","year":"2015","unstructured":"Nguyen, T. L., Vieira-Silva, S., Liston, A. & Raes, J. How informative is the mouse for human gut microbiota research? Dis. Model. Mech. 8, 1\u201316 (2015).","journal-title":"Dis. Model. Mech."},{"key":"395_CR60","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ismej.2010.110","volume":"4","author":"JJ Faith","year":"2010","unstructured":"Faith, J. J. et al. Creating and characterizing communities of human gut microbes in gnotobiotic mice. ISME J. 4, 1094\u20131098 (2010).","journal-title":"ISME J."},{"key":"395_CR61","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nature05414","volume":"444","author":"PJ Turnbaugh","year":"2006","unstructured":"Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027\u20131031 (2006).","journal-title":"Nature"},{"key":"395_CR62","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.0954-6820.1958.tb19115.x","volume":"341","author":"N Svartz","year":"1958","unstructured":"Svartz, N. Treatment of rheumatoid arthritis with salicylazosulfapyridine. Acta Med. Scand. Suppl. 341, 247\u2013254 (1958).","journal-title":"Acta Med. Scand. Suppl."},{"key":"395_CR63","first-page":"180","volume":"4","author":"N Svartz","year":"1948","unstructured":"Svartz, N. The treatment of rheumatic polyarthritis with acid azo compounds. Rheumatism 4, 180\u2013185 (1948).","journal-title":"Rheumatism"},{"key":"395_CR64","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2165\/00003088-197601060-00002","volume":"1","author":"KM Das","year":"1976","unstructured":"Das, K. M. & Dubin, R. Clinical pharmacokinetics of sulphasalazine. Clin. Pharmacokinet. 1, 406\u2013425 (1976).","journal-title":"Clin. Pharmacokinet."},{"key":"395_CR65","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1002\/jps.24103","volume":"103","author":"T Sousa","year":"2014","unstructured":"Sousa, T. et al. On the colonic bacterial metabolism of azo-bonded prodrugs of 5-aminosalicylic acid. J. Pharm. Sci. 103, 3171\u20133175 (2014).","journal-title":"J. Pharm. Sci."},{"key":"395_CR66","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/0006-2952(72)90125-6","volume":"21","author":"DM Valerino","year":"1972","unstructured":"Valerino, D. M., Johns, D. G., Zaharko, D. S. & Oliverio, V. T. Studies of the metabolism of methotrexate by intestinal flora\u2014I: Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10-methylpteroic acid. Biochem. Pharmacol. 21, 821\u2013831 (1972).","journal-title":"Biochem. Pharmacol."},{"key":"395_CR67","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1126\/science.166.3907.887","volume":"166","author":"DS Zaharko","year":"1969","unstructured":"Zaharko, D. S., Bruckner, H. & Oliverio, V. T. Antibiotics alter methotrexate metabolism and excretion. Science 166, 887\u2013888 (1969).","journal-title":"Science"},{"key":"395_CR68","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1240537","volume":"342","author":"S Viaud","year":"2013","unstructured":"Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971\u2013976 (2013).","journal-title":"Science"},{"key":"395_CR69","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.1240527","volume":"342","author":"N Iida","year":"2013","unstructured":"Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967\u2013970 (2013).","journal-title":"Science"},{"key":"395_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10391","volume":"7","author":"K Dubin","year":"2016","unstructured":"Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).","journal-title":"Nat. Commun."},{"key":"395_CR71","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28, 1368\u20131379 (2017).","journal-title":"Ann. Oncol."},{"key":"395_CR72","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"395_CR73","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"395_CR74","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"395_CR75","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M Vetizou","year":"2015","unstructured":"Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079\u20131084 (2015).","journal-title":"Science"},{"key":"395_CR76","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med. 24, 1804\u20131808 (2018).","journal-title":"Nat. Med."},{"key":"395_CR77","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/acr.23467","volume":"71","author":"MH Smith","year":"2017","unstructured":"Smith, M. H. & Bass A. R. Arthritis after cancer immunotherapy: symptom duration and treatment response. Arthritis Care Res. 71, 362\u2013366 (2017).","journal-title":"Arthritis Care Res."},{"key":"395_CR78","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","volume":"48","author":"LC Cappelli","year":"2018","unstructured":"Cappelli, L. C. et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin. Arthritis Rheum. 48, 553\u2013557 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"395_CR79","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41385-018-0050-3","volume":"11","author":"S Paramsothy","year":"2018","unstructured":"Paramsothy, S., Rosenstein, A. K., Mehandru, S. & Colombel, J. F. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol. 11, 1558\u20131570 (2018).","journal-title":"Mucosal Immunol."},{"key":"395_CR80","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/ecco-jcc\/jjw051","volume":"10","author":"MK Magnusson","year":"2016","unstructured":"Magnusson, M. K. et al. Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J. Crohns Colitis 10, 943\u2013952 (2016).","journal-title":"J. Crohns Colitis"},{"key":"395_CR81","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.chom.2017.04.010","volume":"21","author":"AN Ananthakrishnan","year":"2017","unstructured":"Ananthakrishnan, A. N. et al. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe 21, 603\u2013610 (2017).","journal-title":"Cell Host Microbe"},{"key":"395_CR82","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn, W. J. et al. Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N. Engl. J. Med. 367, 1519\u20131528 (2012).","journal-title":"N. Engl. J. Med."},{"key":"395_CR83","doi-asserted-by":"publisher","first-page":"14728","DOI":"10.1073\/pnas.0904489106","volume":"106","author":"TA Clayton","year":"2009","unstructured":"Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R. & Nicholson, J. K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl Acad. Sci. USA 106, 14728\u201314733 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"395_CR84","doi-asserted-by":"publisher","first-page":"14187","DOI":"10.1073\/pnas.0907721106","volume":"106","author":"ID Wilson","year":"2009","unstructured":"Wilson, I. D. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc. Natl Acad. Sci. USA 106, 14187\u201314188 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"395_CR85","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.phrs.2012.07.009","volume":"69","author":"HJ Haiser","year":"2013","unstructured":"Haiser, H. J. & Turnbaugh, P. J. Developing a metagenomic view of xenobiotic metabolism. Pharmacol. Res. 69, 21\u201331 (2013).","journal-title":"Pharmacol. Res."},{"key":"395_CR86","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1111\/bph.13571","volume":"174","author":"A Ryan","year":"2017","unstructured":"Ryan, A. Azoreductases in drug metabolism. Br. J. Pharmacol. 174, 2161\u20132173 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"395_CR87","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.anaerobe.2011.12.006","volume":"18","author":"JM Morrison","year":"2012","unstructured":"Morrison, J. M., Wright, C. M. & John, G. H. Identification, isolation and characterization of a novel azoreductase from clostridium perfringens. Anaerobe 18, 229\u2013234 (2012).","journal-title":"Anaerobe"},{"key":"395_CR88","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.pep.2003.12.016","volume":"34","author":"H Chen","year":"2004","unstructured":"Chen, H., Wang, R. F. & Cerniglia, C. E. Molecular cloning, overexpression, purification, and characterization of an aerobic FMN-dependent azoreductase from Enterococcus faecalis. Protein Expr. Purif. 34, 302\u2013310 (2004).","journal-title":"Protein Expr. Purif."},{"key":"395_CR89","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1128\/JB.183.11.3417-3427.2001","volume":"183","author":"C Delomenie","year":"2001","unstructured":"Delomenie, C. et al. Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J. Bacteriol. 183, 3417\u20133427 (2001).","journal-title":"J. Bacteriol."},{"key":"395_CR90","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1111\/bph.12598","volume":"171","author":"E Sim","year":"2014","unstructured":"Sim, E., Abuhammad, A. & Ryan, A. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br. J. Pharmacol. 171, 2705\u20132725 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"395_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23571-4","volume":"8","author":"T Bazin","year":"2018","unstructured":"Bazin, T. et al. Microbiota composition may predict anti-TNF alpha response in spondyloarthritis patients: an exploratory study. Sci. Rep. 8, 5446 (2018).","journal-title":"Sci. Rep."},{"key":"395_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-017-0267-5","volume":"5","author":"D Kim","year":"2017","unstructured":"Kim, D. et al. Optimizing methods and dodging pitfalls in microbiome research. Microbiome 5, 52 (2017).","journal-title":"Microbiome"},{"key":"395_CR93","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/annrheumdis-2018-214381","volume":"78","author":"LM Rehaume","year":"2019","unstructured":"Rehaume, L. M. et al. IL-23 favours outgrowth of spondyloarthritis-associated pathobionts and suppresses host support for homeostatic microbiota. Ann. Rheum. Dis. 78, 494\u2013503 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"395_CR94","doi-asserted-by":"publisher","unstructured":"Manasson, J. et al. IL-17 inhibition in spondyloarthritis associates with subclinical gut microbiome perturbations and a distinctive IL-25-driven intestinal inflammation. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41169 (2019).","DOI":"10.1002\/art.41169"},{"key":"395_CR95","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bjd.15015","volume":"177","author":"DM Saunte","year":"2017","unstructured":"Saunte, D. M., Mrowietz, U., Puig, L. & Zachariae, C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br. J. Dermatol. 177, 47\u201362 (2017).","journal-title":"Br. J. Dermatol."},{"key":"395_CR96","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3109\/1040841X.2013.810587","volume":"41","author":"R Gerard","year":"2015","unstructured":"Gerard, R., Sendid, B., Colombel, J. F., Poulain, D. & Jouault, T. An immunological link between Candida albicans colonization and Crohn\u2019s disease. Crit. Rev. Microbiol. 41, 135\u2013139 (2015).","journal-title":"Crit. Rev. Microbiol."},{"key":"395_CR97","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/gutjnl-2012-304154","volume":"62","author":"JF Colombel","year":"2013","unstructured":"Colombel, J. F., Sendid, B., Jouault, T. & Poulain, D. Secukinumab failure in Crohn\u2019s disease: the yeast connection? Gut 62, 800\u2013801 (2013).","journal-title":"Gut"},{"key":"395_CR98","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.autrev.2014.08.026","volume":"13","author":"EG Favalli","year":"2014","unstructured":"Favalli, E. G., Biggioggero, M. & Meroni, P. L. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an \u201canchor\u201d drug? Autoimmun. Rev. 13, 1102\u20131108 (2014).","journal-title":"Autoimmun. Rev."},{"key":"395_CR99","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha, D. & Smolen, J. S. Diagnosis and management of rheumatoid arthritis: a review. JAMA 320, 1360\u20131372 (2018).","journal-title":"JAMA"},{"key":"395_CR100","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh, J. A. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68, 1\u201326 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"395_CR101","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","author":"JS Smolen","year":"2020","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655 (2020).","journal-title":"Ann. Rheum. Dis"},{"key":"395_CR102","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/annrheumdis-2012-201612","volume":"72","author":"J Detert","year":"2013","unstructured":"Detert, J. et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann. Rheum. Dis. 72, 844\u2013850 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"395_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-018-2302-5","volume":"19","author":"CD Hughes","year":"2018","unstructured":"Hughes, C. D., Scott, D. L. & Ibrahim, F. Titrate Programme Investigators. Intensive therapy and remissions in rheumatoid arthritis: a systematic review. BMC Musculoskelet. Disord. 19, 389 (2018).","journal-title":"BMC Musculoskelet. Disord."},{"key":"395_CR104","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","volume":"383","author":"JS Smolen","year":"2014","unstructured":"Smolen, J. S. et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 383, 321\u2013332 (2014).","journal-title":"Lancet"},{"key":"395_CR105","first-page":"272","volume":"33","author":"SM Goodman","year":"2015","unstructured":"Goodman, S. M., Cronstein, B. N. & Bykerk, V. P. Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clin. Exp. Rheumatol. 33, 272\u2013278 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"395_CR106","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard.53.7.475","volume":"53","author":"C Lebbe","year":"1994","unstructured":"Lebbe, C., Beyeler, C., Gerber, N. J. & Reichen, J. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann. Rheum. Dis. 53, 475\u2013477 (1994).","journal-title":"Ann. Rheum. Dis."},{"key":"395_CR107","first-page":"S27","volume":"28","author":"EN van Roon","year":"2010","unstructured":"van Roon, E. N. & van de Laar, M. A. Methotrexate bioavailability. Clin. Exp. Rheumatol. 28, S27\u201332 (2010).","journal-title":"Clin. Exp. Rheumatol."},{"key":"395_CR108","doi-asserted-by":"publisher","first-page":"978396","DOI":"10.1155\/2012\/978396","volume":"2012","author":"KI Halilova","year":"2012","unstructured":"Halilova, K. I. et al. Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int. J. Rheumatol. 2012, 978396 (2012).","journal-title":"Int. J. Rheumatol."},{"key":"395_CR109","first-page":"313","volume":"17","author":"P Angelis-Stoforidis","year":"1999","unstructured":"Angelis-Stoforidis, P., Vajda, F. J. & Christophidis, N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin. Exp. Rheumatol. 17, 313\u2013320 (1999).","journal-title":"Clin. Exp. Rheumatol."},{"key":"395_CR110","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1002\/art.20460","volume":"50","author":"T Dervieux","year":"2004","unstructured":"Dervieux, T. et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50, 2766\u20132774 (2004).","journal-title":"Arthritis Rheum."},{"key":"395_CR111","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s11926-010-0120-3","volume":"12","author":"MI Danila","year":"2010","unstructured":"Danila, M. I. et al. Measurement of erythrocyte methotrexate polyglutamate levels: ready for clinical use in rheumatoid arthritis? Curr. Rheumatol. Rep. 12, 342\u2013347 (2010).","journal-title":"Curr. Rheumatol. Rep."},{"key":"395_CR112","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/art.27201","volume":"62","author":"LK Stamp","year":"2010","unstructured":"Stamp, L. K. et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum. 62, 359\u2013368 (2010).","journal-title":"Arthritis Rheum."},{"key":"395_CR113","first-page":"1709","volume":"35","author":"N Hornung","year":"2008","unstructured":"Hornung, N., Ellingsen, T., Attermann, J., Stengaard-Pedersen, K. & Poulsen, J. H. Patients with rheumatoid arthritis treated with methotrexate (methotrexate): concentrations of steady-state erythrocyte methotrexate correlate to plasma concentrations and clinical efficacy. J. Rheumatol. 35, 1709\u20131715 (2008).","journal-title":"J. Rheumatol."},{"key":"395_CR114","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13075-018-1544-9","volume":"20","author":"J Bluett","year":"2018","unstructured":"Bluett, J. et al. Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study. Arthritis Res. Ther. 20, 50 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"395_CR115","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/rheumatology\/key263","volume":"58","author":"JS Dekkers","year":"2019","unstructured":"Dekkers, J. S. et al. Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis. Rheumatology 58, 149\u2013153 (2019).","journal-title":"Rheumatology"},{"key":"395_CR116","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/ard.2008.088237","volume":"68","author":"SL Hider","year":"2009","unstructured":"Hider, S. L. et al. Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann. Rheum. Dis. 68, 57\u201362 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"395_CR117","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13075-018-1645-5","volume":"20","author":"JC Sergeant","year":"2018","unstructured":"Sergeant, J. C. et al. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res. Ther. 20, 147 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"395_CR118","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1111\/1756-185X.13333","volume":"21","author":"V Gupta","year":"2018","unstructured":"Gupta, V., Katiyar, S., Singh, A., Misra, R. & Aggarwal, A. CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis. Int. J. Rheum. Dis. 21, 1548\u20131556 (2018).","journal-title":"Int. J. Rheum. Dis."},{"key":"395_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25634-y","volume":"8","author":"R Lopez-Rodriguez","year":"2018","unstructured":"Lopez-Rodriguez, R. et al. Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci. Rep. 8, 7342 (2018).","journal-title":"Sci. Rep."},{"key":"395_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208534","volume":"13","author":"M de Rotte","year":"2018","unstructured":"de Rotte, M. et al. Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis. PLoS One 13, e0208534 (2018).","journal-title":"PLoS One"},{"key":"395_CR121","doi-asserted-by":"publisher","unstructured":"Plant D. et al. Gene expression profiling identifies classifier of methotrexate non-response in patients with rheumatoid arthritis. Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.40810 (2019).","DOI":"10.1002\/art.40810"},{"key":"395_CR122","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/art.22640","volume":"56","author":"JA Wessels","year":"2007","unstructured":"Wessels, J. A. et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56, 1765\u20131775 (2007).","journal-title":"Arthritis Rheum."},{"key":"395_CR123","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2217\/pgs-2018-0144","volume":"20","author":"F Eektimmerman","year":"2019","unstructured":"Eektimmerman, F. et al. Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients. Pharmacogenomics 20, 85\u201393 (2019).","journal-title":"Pharmacogenomics"},{"key":"395_CR124","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fphar.2018.00020","volume":"9","author":"B Jenko","year":"2018","unstructured":"Jenko, B. et al. Clinical pharmacogenetic models of treatment response to methotrexate monotherapy in Slovenian and Serbian rheumatoid arthritis patients: differences in patient\u2019s management may preclude generalization of the models. Front. Pharmacol. 9, 20 (2018).","journal-title":"Front. Pharmacol."},{"key":"395_CR125","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41397-018-0017-5","volume":"18","author":"R Lopez-Rodriguez","year":"2018","unstructured":"Lopez-Rodriguez, R. et al. Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis. Pharmacogenomics J. 18, 539\u2013545 (2018).","journal-title":"Pharmacogenomics J."},{"key":"395_CR126","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nm.3914","volume":"21","author":"X Zhang","year":"2015","unstructured":"Zhang, X. et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat. Med. 21, 895\u2013905 (2015).","journal-title":"Nat. Med."},{"key":"395_CR127","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/jac\/dkw383","volume":"72","author":"S Isaac","year":"2017","unstructured":"Isaac, S. et al. Short- and long-term effects of oral vancomycin on the human intestinal microbiota. J. Antimicrob. Chemother. 72, 128\u2013136 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"395_CR128","doi-asserted-by":"publisher","DOI":"10.1101\/600155","author":"RR Nayak","year":"2019","unstructured":"Nayak, R. R. et al. Perturbation of the human gut microbiome by a non-antibiotic drug contributes to the resolution of autoimmune disease. bioRxiv https:\/\/doi.org\/10.1101\/600155 (2019).","journal-title":"bioRxiv"},{"key":"395_CR129","first-page":"2769","volume":"71","author":"S Isaac","year":"2019","unstructured":"Isaac, S. et al. The pre-treatment gut microbiome predicts early response to methotrexate in rheumatoid arthritis [abstract]. Arthritis Rheumatol. 71, 2769 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"395_CR130","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2018.20046","volume":"321","author":"SP Costello","year":"2019","unstructured":"Costello, S. P. et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321, 156\u2013164 (2019).","journal-title":"JAMA"},{"key":"395_CR131","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","volume":"389","author":"S Paramsothy","year":"2017","unstructured":"Paramsothy, S. et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389, 1218\u20131228 (2017).","journal-title":"Lancet"},{"key":"395_CR132","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019231","volume":"8","author":"MS Kragsnaes","year":"2018","unstructured":"Kragsnaes, M. S. et al. Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial. BMJ Open 8, e019231 (2018).","journal-title":"BMJ Open"},{"key":"395_CR133","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1242\/dev.101048","volume":"141","author":"N Gjorevski","year":"2014","unstructured":"Gjorevski, N., Ranga, A. & Lutolf, M. P. Bioengineering approaches to guide stem cell-based organogenesis. Development 141, 1794\u20131804 (2014).","journal-title":"Development"},{"key":"395_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00259-3","volume":"8","author":"SJ Trietsch","year":"2017","unstructured":"Trietsch, S. J. et al. Membrane-free culture and real-time barrier integrity assessment of perfused intestinal epithelium tubes. Nat. Commun. 8, 262 (2017).","journal-title":"Nat. Commun."},{"key":"395_CR135","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nbt.2989","volume":"32","author":"SN Bhatia","year":"2014","unstructured":"Bhatia, S. N. & Ingber, D. E. Microfluidic organs-on-chips. Nat. Biotechnol. 32, 760\u2013772 (2014).","journal-title":"Nat. Biotechnol."},{"key":"395_CR136","doi-asserted-by":"publisher","first-page":"16203","DOI":"10.1038\/nmicrobiol.2016.203","volume":"1","author":"JC Lagier","year":"2016","unstructured":"Lagier, J. C. et al. Culture of previously uncultured members of the human gut microbiota by culturomics. Nat. Microbiol. 1, 16203 (2016).","journal-title":"Nat. Microbiol."},{"key":"395_CR137","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nature25979","volume":"555","author":"L Maier","year":"2018","unstructured":"Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623\u2013628 (2018).","journal-title":"Nature"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0395-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0395-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0395-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T22:37:01Z","timestamp":1722551821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0395-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":137,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1038\/s41584-020-0395-3","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,10]]},"assertion":[{"value":"12 February 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.U.S. declares that he has served as a consultant for Amgen, BMS, Janssen, Novartis, Sanofi and UCB, and has received funds from Novartis to NYU School of Medicine to conduct investigator-initiated studies. J.U.S. and S.B.A. have been granted USPTO patent no. 10011883 (\u201cCausative agents and diagnostic methods relating to rheumatoid arthritis\u201d). P.J.T. declares he is on the scientific advisory boards for Kaleido, Seres, SNIPRbiome, uBiome, and WholeBiome; there is no direct overlap between the current article and these consulting duties. R.R.N. and C.U. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}